Reid Laurence's Form 4 filing
Metagenomi Therapeutics, Inc. (MGX) · filed Sep 11, 2026
- Accession no.
- 0001193125-26-389550
- Filed
- Sep 11, 2026, 7:51 PM ET
- Trade date
- Sep 9, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $23.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reid LaurenceCIK 0001492749 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Common Stock | PPurchaseAcquired | +19,883 | $1.17F1 | +$23,263.11 | 19,883 | Direct | |
| Sep 9, 2026 | Common Stock | PPurchaseAcquired | +117 | $1.18 | +$138.06 | 20,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.